Immunome Inc.

Immunome Inc. reported a net loss of $53.8 million for the first quarter of 2026, widening from $41.6 million in Q1 2025, primarily due to increased research and development expenses and the termination of collaboration revenue. The company's cash and cash equivalents stood at $582.7 million as of March 31, 2026, down from $653.5 million at the end of 2025. Immunome expects its current cash to fund operations for at least 12 months, while continuing to invest in its targeted oncology therapies.

Immunome Inc. reported its first-quarter 2026 financial results and provided a comprehensive business update. The company submitted a New Drug Application (NDA) to the U.S. FDA in April 2026 for varegacestat for desmoid tumors, following positive Phase 3 RINGSIDE data. Immunome also advanced its ADC pipeline with IND clearance for IM-1617 and ongoing Phase 1 trials for IM-1021 and IM-3050. For Q1 2026, the company reported a net loss of $53.8 million and ended the quarter with $582.7 million in cash, expected to fund operations into 2028.

Immunome Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 9, 2026, to elect three Class III directors, ratify Ernst & Young LLP as auditor, and conduct advisory votes on executive compensation and its frequency. The company highlighted a defining 2025 with positive Phase 3 RINGSIDE trial data for varegacestat, leading to a planned Q2 2026 NDA filing. Immunome also advanced its ADC portfolio and received IND clearance for IM-3050, with further pipeline progress expected in 2026.